Table of Contents Author Guidelines Submit a Manuscript
Depression Research and Treatment
Volume 2011 (2011), Article ID 680194, 7 pages
http://dx.doi.org/10.1155/2011/680194
Research Article

Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability

Centre for Personality Disorders, Unit of Psychiatry 1, Department of Neurosciences, University of Turin, via Cherasco 11, 10126 Turin, Italy

Received 5 April 2011; Accepted 15 June 2011

Academic Editor: Axel Steiger

Copyright © 2011 Silvio Bellino et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC, USA, 4th edition, 2000, Text Revision (DSM-IV-TR).
  2. American Psychiatric Association, Practice Guidelines for the Treatment of Patients with Borderline Personality Disorder, American Psychiatric Association, Arlington, Va, USA, 2001.
  3. J. M. Oldham, Guideline Watch: Practice Guideline for the Treatment of Patients with Borderline Personality Disorder, American Psychiatric Association, Arlington, Va, USA, 2005.
  4. H. Y. Meltzer and S. R. McGurk, “The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia,” Schizophrenia Bulletin, vol. 25, no. 2, pp. 233–255, 1999. View at Google Scholar · View at Scopus
  5. C. U. Correll, S. Leucht, and J. M. Kane, “Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies,” American Journal of Psychiatry, vol. 161, no. 3, pp. 414–425, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Van Den Eynde, S. De Saedeleer, K. Naudts et al., “Quetiapine treatment and improved cognitive functioning in borderline personality disorder,” Human Psychopharmacology, vol. 24, no. 8, pp. 646–649, 2009. View at Publisher · View at Google Scholar · View at PubMed
  7. E. M. Szigethy and S. C. Schulz, “Risperidone in comorbid borderline personality disorder and dysthymia,” Journal of Clinical Psychopharmacology, vol. 17, no. 4, pp. 326–327, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Rocca, L. Marchiaro, E. Cocuzza, and F. Bogetto, “Treatment of borderline personality disorder with risperidone,” Journal of Clinical Psychiatry, vol. 63, no. 3, pp. 241–244, 2002. View at Google Scholar · View at Scopus
  9. R. O. Friedel, W. T. Jackson, C. S. Huston, R. S. May, N. L. Kirby, and A. Stoves, “Risperidone treatment of borderline personality disorder assessed by a borderline personality disorder-specific outcome measure: a pilot study,” Journal of Clinical Psychopharmacology, vol. 28, no. 3, pp. 345–347, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. Jutila, T. Söderlund, A. L. Pakkanen, M. Huttunen, and P. K. J. Kinnunen, “Comparison of the effects of clozapine, chlorpromazine, and haloperidol on membrane lateral heterogeneity,” Chemistry and Physics of Lipids, vol. 112, no. 2, pp. 151–163, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. A. A. H. P. Megens, F. H. L. Awouters, A. Schotte et al., “Survey on the pharmacodynamics of the new antipsychotic risperidone,” Psychopharmacology, vol. 114, no. 1, pp. 9–23, 1994. View at Google Scholar · View at Scopus
  12. A. Schotte, P. F. M. Janssen, W. Gommeren et al., “Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding,” Psychopharmacology, vol. 124, no. 1-2, pp. 57–73, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. J. E. Leysen, “Receptor profile of antipsychotics,” in Atypical Antipsychotics, B. A. Ellenbroek and A. R. Cools, Eds., pp. 57–81, Birkäuser, Basel, Switzerland, 2000. View at Google Scholar
  14. M. Vermeir, S. Boom, I. Naessens, K. Talluri, and M. Eerdekens, “Absorbtion, metabolism and excretion of a single oral dose of 14C-paliperidone 1mg in healthy subjects,” European Neuropsychopharmacology, vol. 30, pp. 191–192, 2005. View at Google Scholar
  15. S. R. Marder, M. Kramer, L. Ford et al., “Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study,” Biological Psychiatry, vol. 62, no. 12, pp. 1363–1370, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. M. Lautenschlager and A. Heinz, “Paliperidone-ER: first atypical antipsychotic with oral extended release formulation,” Expert Review of Neurotherapeutics, vol. 8, no. 2, pp. 193–200, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. H. A. Nasrallah, “Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles,” Molecular Psychiatry, vol. 13, no. 1, pp. 27–35, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. R. Knegtering, P. Baselmans, S. Castelein, F. Bosker, R. Bruggeman, and R. J. Van Den Bosch, “Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels,” American Journal of Psychiatry, vol. 162, no. 5, pp. 1010–1012, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. K. I. Melkersson, “Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite,” Human Psychopharmacology, vol. 21, no. 8, pp. 529–532, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. J. Kane, F. Canas, M. Kramer et al., “Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial,” Schizophrenia Research, vol. 90, no. 1–3, pp. 147–161, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. Davidson, R. Emsley, M. Kramer et al., “Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study,” Schizophrenia Research, vol. 93, no. 1–3, pp. 117–130, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. C. Dolder, M. Nelson, and Z. Deyo, “Paliperidone for schizophrenia,” American Journal of Health-System Pharmacy, vol. 65, no. 5, pp. 403–413, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. J. Berwaerts, A. Cleton, S. Rossenu et al., “A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia,” Journal of Psychopharmacology, vol. 24, no. 7, pp. 1011–1018, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. P. Karlsson, E. Dencker, and S. Nyberg, “Pharmacokinetic and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects,” European Neuropsychopharmacology, vol. 15, p. 385, 2005. View at Google Scholar
  25. P. Karlsson, E. Dencker, S. Nyberg et al., “Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects,” Schizophrenia Research, vol. 81, no. 1, pp. 85–86, 2006. View at Google Scholar
  26. R. Conley, S. K. Gupta, and G. Sathyan, “Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form,” Current Medical Research and Opinion, vol. 22, no. 10, pp. 1879–1892, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. C. M. Canuso, C. A. Bossie, I. Turkoz, and L. Alphs, “Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms,” Schizophrenia Research, vol. 113, no. 1, pp. 56–64, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. L. Pani and G. Marchese, “Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release,” Expert Opinion on Drug Delivery, vol. 6, no. 3, pp. 319–331, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. H. Y. Meltzer, W. V. Bobo, I. F. Nuamah et al., “Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies,” Journal of Clinical Psychiatry, vol. 69, no. 5, pp. 817–829, 2008. View at Google Scholar · View at Scopus
  30. M. B. First, M. Gibbon, R. L. Spitzer, J. B. W. Williams, and L. S. Benjamin, Structured Clinical Interview for DSM-IV disorders Axis II (SCID-II), American Psychiatric Press, Arlington, Va, USA, 1997.
  31. W. Guy, “Clinical global impression (C.G.I.),” in ECDEU Assessment Manual for Psychopharmacology, US Dept Health, Education, and Welfare publication (ADM), Ed., pp. 218–222, National Institute of Mental Health, Rockville, Md, USA, 1976. View at Google Scholar
  32. J. Ventura, M. Green, A. Shaner, and R. Liberman, “Training and quality assurance with the Brief Psychiatry Rating Scale: “the drift busters”,” International Journal of Psychiatric Research, vol. 3, p. 221, 1993. View at Google Scholar
  33. M. Hamilton, “A rating scale for depression,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 23, pp. 56–62, 1960. View at Google Scholar · View at Scopus
  34. M. Hamilton, “The assessment of anxiety states by rating,” The British Journal of Medical Psychology, vol. 32, no. 1, pp. 50–55, 1959. View at Google Scholar · View at Scopus
  35. H. H. Goldman, A. E. Skodol, and T. R. Lave, “Revising axis V for DSM-IV: a review of measures of social functioning,” American Journal of Psychiatry, vol. 149, no. 9, pp. 1148–1156, 1992. View at Google Scholar · View at Scopus
  36. E. S. Barratt, “Factor analysis of some psychometric measures of impulsiveness and anxiety,” Psychological Reports, vol. 16, pp. 547–554, 1965. View at Google Scholar · View at Scopus
  37. A. Arntz, M. Van den Hoorn, J. Cornelis, R. Verheul, W. M. C. Van den Bosch, and A. J. H. T. De Bie, “Reliability and validity of the borderline personality disorder severity index,” Journal of Personality Disorders, vol. 17, no. 1, pp. 45–59, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. E. S. Barratt, “Impulsiveness and aggression,” in Violence and Mental Disorder: Developments in Risk Assessment, J. Monahan and H. J. Steadman, Eds., pp. 61–79, University of Chicago Press, Chicago, Ill, USA, 1994. View at Google Scholar
  39. J. H. Patton, M. S. Stanford, and E. S. Barratt, “Factor structure of the Barratt Impulsiveness Scale,” Journal of Clinical Psychology, vol. 51, no. 6, pp. 768–774, 1994. View at Google Scholar · View at Scopus
  40. A. Fossati, A. Di Ceglie, E. Acquarini, and E. S. Barratt, “Psychometric properties of an Italian version of the Barrat Impulsiveness Scale-11 (BIS-11) in nonclinical subjects,” Journal of Clinical Psychology, vol. 57, no. 6, pp. 815–828, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. W. Guy, “Dosage Record and Treatment Emergent Symptoms scale (DOTES),” in ECDEU Assessment Manual for Psychopharmacology—Revised, US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Ed., pp. 223–244, National Institute of Mental Health, Rockville, Md, USA, 1976. View at Google Scholar
  42. P. M. Haddad and A. Wieck, “Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management,” Drugs, vol. 64, no. 20, pp. 2291–2314, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Mancini, F. F. Casanueva, and A. Giustina, “Hyperprolactinemia and prolactinomas,” Endocrinology and Metabolism Clinics of North America, vol. 37, no. 1, pp. 67–99, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. C. A. Harrington and C. English, “Tolerability of paliperidone: a meta-analysis of randomized, controlled trials,” International Clinical Psychopharmacology, vol. 25, no. 6, pp. 334–341, 2010. View at Publisher · View at Google Scholar · View at PubMed
  45. M. Díaz-Marsá, M. Galian, A. Montes et al., “Long-acting injectable risperidone in treatment resistant borderline personality disorder. A small series report,” Actas Espanolas de Psiquiatria, vol. 36, no. 2, pp. 70–74, 2008. View at Google Scholar · View at Scopus
  46. F. R. Frankerburg and M. C. Zanarini, “Clozapine treatment of borderline patients: a preliminary study,” Comprehensive Psychiatry, vol. 34, no. 6, pp. 402–405, 1993. View at Publisher · View at Google Scholar · View at Scopus
  47. G. F. Parker, “Clozapine and borderline personality disorder,” Psychiatric Services, vol. 53, no. 3, pp. 348–349, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. S. C. Schulz, K. L. Camlin, S. A. Berry, and J. A. Jesberger, “Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia,” Biological Psychiatry, vol. 46, no. 10, pp. 1429–1435, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. M. P. Bogenschutz and H. G. Nurnberg, “Olanzapine versus placebo in the treatment of borderline personality disorder,” Journal of Clinical Psychiatry, vol. 65, no. 1, pp. 104–109, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Adityanjee and S. C. Schulz, “Clinical use of quetiapine in disease states other than schizophrenia,” Journal of Clinical Psychiatry, vol. 63, no. 13, pp. 32–38, 2002. View at Google Scholar · View at Scopus
  51. E. Hilger, C. Barnas, and S. Kasper, “Quetiapine in the treatment of borderline personality disorder,” The World Journal of Biological Psychiatry, vol. 4, no. 1, pp. 42–44, 2003. View at Google Scholar · View at Scopus
  52. E. Villeneuve and S. Lemelin, “Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target,” Journal of Clinical Psychiatry, vol. 66, no. 10, pp. 1298–1303, 2005. View at Google Scholar · View at Scopus
  53. S. Bellino, E. Paradiso, and F. Bogetto, “Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study,” Journal of Clinical Psychiatry, vol. 67, no. 7, pp. 1042–1046, 2006. View at Google Scholar · View at Scopus
  54. C. Perrella, D. Carrus, E. Costa, and F. Schifano, “Quetiapine for the treatment of borderline personality disorder; an open-label study,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 1, pp. 158–163, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. A. Adityanjee, A. Romine, E. Brown, P. Thuras, S. Lee, and S. C. Schulz, “Quetiapine in patients with borderline personality disorder: an open-label trial,” Annals of Clinical Psychiatry, vol. 20, no. 4, pp. 219–226, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. F. Van Den Eynde, V. Senturk, K. Naudts et al., “Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder,” Journal of Clinical Psychopharmacology, vol. 28, no. 2, pp. 147–155, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. A. Mobascher, J. Mobascher, V. Schlemper, G. Winterer, and J. Malevani, “Aripiprazole pharmacotherapy of borderline personality disorder: a series of three consecutive case reports,” Pharmacopsychiatry, vol. 39, no. 3, pp. 111–112, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. M. K. Nickel, M. Muehlbacher, C. Nickel et al., “Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study,” American Journal of Psychiatry, vol. 163, no. 5, pp. 833–838, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. M. K. Nickel, “Aripiprazole treatment of patients with borderline personality disorder,” Journal of Clinical Psychiatry, vol. 68, no. 11, pp. 1815–1816, 2007. View at Google Scholar · View at Scopus
  60. S. Bellino, E. Paradiso, and F. Bogetto, “Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder,” Psychiatry Research, vol. 161, no. 2, pp. 206–212, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. M. C. Zanarini, F. R. Frankenburg, and E. A. Parachini, “A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder,” Journal of Clinical Psychiatry, vol. 65, no. 7, pp. 903–907, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Soler, J. C. Pascual, J. Campins et al., “Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder,” American Journal of Psychiatry, vol. 162, no. 6, pp. 1221–1224, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. F. Benedetti, L. Sforzini, C. Colombo, C. Maffei, and E. Smeraldi, “Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder,” Journal of Clinical Psychiatry, vol. 59, no. 3, pp. 103–107, 1998. View at Google Scholar · View at Scopus
  64. M. C. Zanarini and F. R. Frankenburg, “Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study,” Journal of Clinical Psychiatry, vol. 62, no. 11, pp. 849–854, 2001. View at Google Scholar
  65. J. C. Pascual, S. Oller, J. Soler, J. Barrachina, E. Alvarez, and V. Pérez, “Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services,” Journal of Clinical Psychiatry, vol. 65, no. 9, pp. 1281–1282, 2004. View at Google Scholar
  66. J. R. Bostwick, S. K. Guthrie, and V. L. Ellingrod, “Antipsychotic-induced hyperprolactinemia,” Pharmacotherapy, vol. 29, no. 1, pp. 64–73, 2009. View at Publisher · View at Google Scholar · View at PubMed
  67. E. Spina and R. Cavallaro, “The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia,” Expert Opinion on Drug Safety, vol. 6, no. 6, pp. 651–662, 2007. View at Publisher · View at Google Scholar · View at PubMed
  68. J. Marino and J. Caballero, “Paliperidone extended-release for the treatment of schizophrenia,” Pharmacotherapy, vol. 28, no. 10, pp. 1283–1298, 2008. View at Publisher · View at Google Scholar · View at PubMed
  69. A. Tzimos, V. Samokhvalov, M. Kramer et al., “Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension,” American Journal of Geriatric Psychiatry, vol. 16, no. 1, pp. 31–43, 2008. View at Publisher · View at Google Scholar · View at PubMed